021-51111890
购物车（0）
sales@molnova.cn
Candoxatril
CAS No. 123122-55-4
Candoxatril ( UK 79300 )
产品货号. M10912 CAS No. 123122-55-4
Candoxatrilat (UK-73967) 的口服活性前药，有效的中性内肽酶 EC 3.4.24.11（心肽酶）抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥7857 | 有现货 |
|
| 50MG | ￥16038 | 有现货 |
|
| 100MG | ￥20250 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Candoxatril
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Candoxatrilat (UK-73967) 的口服活性前药，有效的中性内肽酶 EC 3.4.24.11（心肽酶）抑制剂。
-
产品描述The orally active prodrug of candoxatrilat (UK-73967), potent neutral endopeptidase EC 3.4.24.11 (atriopeptidase) inhibitor.Heart Failure Discontinued.
-
体外实验——
-
体内实验While the NEP inhibitors have no significant effect on body weight, food and water intake, mean blood pressure or creatinine levels, they do increase cGMP levels in the urine and affected hematopoiesis in an anti-inflammatory way. Moreover, a-SMA deposition in the kidney cortex is inversely correlated with cGMP elevation suggesting a NEP dependent antifibroti effect. High quality mRNA profiles are obtained with at least 8 independent samples per treatment group. The data confirms the cGMP dependent anti-fibrotic action of Sol-1 and further supports the potential therapeutic actions of this neutral endopeptidase inhibitor.
-
同义词UK 79300
-
通路Metabolic Enzyme/Protease
-
靶点Neprilysin
-
受体Neprilysin
-
研究领域——
-
适应症——
化学信息
-
CAS Number123122-55-4
-
分子量515.638
-
分子式C29H41NO7
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCOCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3
-
化学全称4-{[(1-{3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Danilewicz JC, et al. Biochem Biophys Res Commun. 1989 Oct 16;164(1):58-65.
2. Shepperson NB, et al. Br J Pharmacol. 1989 Dec;98 Suppl:822P.
3. Jardine AG, et al. Am J Hypertens. 1990 Sep;3(9):661-7.
4. Northridge DB, et al. Lancet. 1989 Sep 9;2(8663):591-3.
